20259
After two decades of research and development activity focussed on orally active kinase inhibitors , the first such drug ( the JAK inhibitor Xeljanz , tofacitinib ) was approved by the FDA in November 2012 for the treatment of rheumatoid arthritis ( RA ) .
 Chemical: Xeljanz; Chemical: tofacitinib
Please list all entity words in the text that fit the category.Output format is "type1: word1; type2: word2". 
Option: Chemical 
Text: {0} 
Answer:
 Chemical: Xeljanz; Chemical: tofacitinib